Back to Screener

NewAmsterdam Pharma Company N.V. Warrant (NAMSW)

Price$24.89
Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-11.89%
Price vs S&P 500 (4W)12.15%
VGM Score66.60

All Metrics

Price vs S&P 500 (YTD)-0.27%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.00M
52-Week Price Return243.61%
52-Week High$30.45
26-Week Price Return1.99%
13-Week Price Return25.29%
3-Month Return Std Dev113.03%
Price vs S&P 500 (52W)219.76%
Year-to-Date Return8.24%
5-Day Price Return-16.99%
Month-to-Date Return17.26%
Price vs S&P 500 (13W)16.42%
Beta6.76x
52-Week Low$7.16
mGradeB
vgmGradeB
Show chart for

Industry Peers — Pharmaceuticals(550)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
NAMSWNewAmsterdam Pharma Company N.V. Warrant
B$24.89
LLYEli Lilly & Co.DBB$1082.20
JNJJohnson & JohnsonCCC$223.51
ABBVABBVIE INC.DCC$212.93
MRKMerck & Co., Inc.CCC$115.17
NVSNovartis AGCCC$145.68
AZNAstraZeneca PLCDBC$179.71
NVONovo-Nordisk A/SBBC$44.07
ABTAbbott LaboratoriesCCD$87.78
PFEPfizer Inc.BCC$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary SharesCCC$34.64

About

NewAmsterdam Pharma is a late-stage biopharmaceutical company developing therapies for cardio-metabolic diseases. Its lead product, obicetrapib, is an oral CETP inhibitor designed to overcome the efficacy and tolerability limitations of current LDL cholesterol-lowering treatments in patients with inadequate response or poor tolerance to existing therapies.